



COMMISSIONER FOR PATENT UNITED STATES PATENT AND TRADEMARK OFFIC P.O. Box 1450

Airc 11 2003

Rec d 9/4/03

David T. Read Acting Director Health Assessment Policy Staff, CDER Food and Drug Administration 1451 Rockville Pike, HFD-7 Rockville, MD 20852

Dear Mr. Read:

Transmitted herewith is a copy of the application for patent term extension of U.S. Patent No. 5,006,528. The application was filed on January 7, 2003, under 35 U.S.C. § 156.

The patent claims a product that was subject to regulatory review under the Federal Food, Drug and Cosmetic Act. Subject to final review, the subject patent is considered to be eligible for patent term restoration. Thus, a determination by your office of the applicable regulatory review period is necessary. Accordingly, notice and a copy of the application are provided pursuant to 35 U.S.C. § 156(d)(2)(A).

Inquiries regarding this communication should be directed to the undersigned at (703) 306-3159 (telephone) or (703)872-9411 (facsimile).

Karin Ferriter

Senior Legal Advisor

Office of Patent Legal Administration Office of the Deputy Commissioner for Patent Examination Policy

cc:

Charles E. Van Horn

Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

1300 I Street, NW

Washington DC 20005-3315

RE: ABILIFY® (aripiprazole)

Docket No. 03E-0150

03E-0150

LET 2